# Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

> **NCT04310943** · PHASE2 · COMPLETED · sponsor: **Zhou Chengzhi** · enrollment: 24 (actual)

## Conditions studied

- Lung Adenocarcinoma Stage IV

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04310943
- **Lead sponsor:** Zhou Chengzhi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04310943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04310943, "Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04310943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*